 Shares of Cytokinetics Inc. soared 33.0 in premarket trading on Monday after the company said a Phase 2 clinical trial for its experimental hypertrophic cardiomyopathy treatment yielded positive results. The still-investigational therapy helped improve blood flow in patients with the disease, which is considered one of the most common reasons for sudden cardiac death in people who are younger than 35. 